The Global Incretin-based Drugs Market was valued at USD 39.4 billion in 2025 and is estimated to grow at a CAGR of 6.4% to reach USD 72.6 billion by 2035.
Growth in the incretin-based drugs industry is closely associated with the accelerating incidence of type 2 diabetes mellitus worldwide, which continues to increase demand for effective long-term treatment options. Medical professionals are progressively shifting toward non-insulin therapeutic approaches that offer improved glycemic control while supporting broader cardiometabolic health. Therapies in this category, including GLP-1 receptor agonists and DPP-4 inhibitors, help regulate blood glucose by stimulating insulin secretion and suppressing glucagon production. In addition, these treatments contribute to weight management and improved cardiovascular health, which has strengthened their clinical acceptance. Continuous improvements in drug delivery technologies, combined with rising awareness about advanced diabetes care, are further encouraging adoption across developed and emerging healthcare systems. As healthcare providers focus on improving treatment outcomes and long-term disease management, incretin-based therapies are increasingly being incorporated into diabetes treatment protocols. This evolving therapeutic landscape is expected to sustain strong demand for incretin-based medications over the coming decade.
The incretin-based drugs market is also benefiting from growing clinical recognition of the cardiometabolic advantages associated with these therapies, particularly within the GLP-1 receptor agonists category. Beyond glucose regulation, these treatments are increasingly valued for their ability to support broader cardiovascular health in individuals living with type 2 diabetes. Medical studies have shown that therapies in this class can help lower the risk of major cardiovascular complications among high-risk patients, which has elevated their position in diabetes care strategies. Additional benefits such as reductions in blood pressure, improvements in lipid metabolism, and anti-inflammatory effects have further strengthened their role in comprehensive cardiometabolic management. Weight management has also become a significant factor influencing treatment decisions, as excess body weight remains a common concern among individuals with diabetes.
The GLP-1 receptor agonists segment generated USD 25.7 billion in 2025. This segment continues to experience strong adoption due to its consistent clinical performance and expanding relevance in metabolic disease management. Treatments within this category are widely recognized for delivering effective glucose control while supporting additional therapeutic outcomes related to cardiovascular health and body weight management. Pharmaceutical companies have strengthened the market presence of GLP-1 receptor agonists through continued product development and expanded global distribution strategies. As these therapies demonstrate reliable outcomes in managing chronic metabolic conditions, healthcare providers are increasingly integrating them into routine treatment plans. Their growing acceptance in both diabetes care and weight-related metabolic management continues to reinforce the segment’s leadership within the incretin-based drugs industry.
Based on route of administration, the oral segment held a 76.7% share in 2025. Oral incretin therapies provide a convenient alternative to injectable formulations, which play an important role in improving patient adherence to long-term treatment. Advancements in oral drug formulation technologies have contributed to improved therapeutic performance, safety profiles, and patient compliance. These medications are also easier to transport, store, and distribute across healthcare facilities, making them suitable for diverse medical environments. Unlike injectable treatments, oral therapies do not require specialized training for self-administration, which helps reduce the burden on healthcare professionals while simplifying treatment routines for patients. In addition, many individuals prefer oral medications because they are more convenient and less invasive.
North America Incretin-based Drugs Market accounted for 45.7% share in 2025. The region continues to demonstrate significant growth potential, primarily due to the increasing number of individuals diagnosed with type 2 diabetes mellitus. The expanding patient population is driving demand for advanced therapeutic solutions capable of delivering sustained blood glucose management while addressing related metabolic challenges. Healthcare providers across the region are increasingly prescribing incretin-based therapies as part of comprehensive diabetes management strategies. These treatments offer effective long-term glycemic control and provide additional benefits such as weight management, which are highly relevant for patients dealing with chronic metabolic conditions. As the healthcare system focuses on improving long-term disease outcomes, incretin-based drugs are gaining broader acceptance among clinicians throughout North America.
Key participants operating in the Global Incretin-based Drugs Market include AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck, Novo Nordisk, Pfizer, Sanofi, Takeda Pharmaceutical Company, and Teva Pharmaceuticals. Companies active in the Incretin-based Drugs Market are implementing several strategic initiatives to reinforce their competitive position and expand global reach. Major pharmaceutical firms are prioritizing research and development investments to advance innovative formulations and improve therapeutic performance. Strategic partnerships and collaborative agreements with research institutions and biotechnology firms are also becoming common, allowing companies to accelerate drug development and expand product pipelines. Market participants are strengthening their presence in emerging healthcare markets through distribution expansion and localized commercialization strategies. In addition, organizations are focusing on regulatory approvals and clinical trials to support new product introductions and broaden therapeutic indications.
This product will be delivered within 2-4 business days.
Growth in the incretin-based drugs industry is closely associated with the accelerating incidence of type 2 diabetes mellitus worldwide, which continues to increase demand for effective long-term treatment options. Medical professionals are progressively shifting toward non-insulin therapeutic approaches that offer improved glycemic control while supporting broader cardiometabolic health. Therapies in this category, including GLP-1 receptor agonists and DPP-4 inhibitors, help regulate blood glucose by stimulating insulin secretion and suppressing glucagon production. In addition, these treatments contribute to weight management and improved cardiovascular health, which has strengthened their clinical acceptance. Continuous improvements in drug delivery technologies, combined with rising awareness about advanced diabetes care, are further encouraging adoption across developed and emerging healthcare systems. As healthcare providers focus on improving treatment outcomes and long-term disease management, incretin-based therapies are increasingly being incorporated into diabetes treatment protocols. This evolving therapeutic landscape is expected to sustain strong demand for incretin-based medications over the coming decade.
The incretin-based drugs market is also benefiting from growing clinical recognition of the cardiometabolic advantages associated with these therapies, particularly within the GLP-1 receptor agonists category. Beyond glucose regulation, these treatments are increasingly valued for their ability to support broader cardiovascular health in individuals living with type 2 diabetes. Medical studies have shown that therapies in this class can help lower the risk of major cardiovascular complications among high-risk patients, which has elevated their position in diabetes care strategies. Additional benefits such as reductions in blood pressure, improvements in lipid metabolism, and anti-inflammatory effects have further strengthened their role in comprehensive cardiometabolic management. Weight management has also become a significant factor influencing treatment decisions, as excess body weight remains a common concern among individuals with diabetes.
The GLP-1 receptor agonists segment generated USD 25.7 billion in 2025. This segment continues to experience strong adoption due to its consistent clinical performance and expanding relevance in metabolic disease management. Treatments within this category are widely recognized for delivering effective glucose control while supporting additional therapeutic outcomes related to cardiovascular health and body weight management. Pharmaceutical companies have strengthened the market presence of GLP-1 receptor agonists through continued product development and expanded global distribution strategies. As these therapies demonstrate reliable outcomes in managing chronic metabolic conditions, healthcare providers are increasingly integrating them into routine treatment plans. Their growing acceptance in both diabetes care and weight-related metabolic management continues to reinforce the segment’s leadership within the incretin-based drugs industry.
Based on route of administration, the oral segment held a 76.7% share in 2025. Oral incretin therapies provide a convenient alternative to injectable formulations, which play an important role in improving patient adherence to long-term treatment. Advancements in oral drug formulation technologies have contributed to improved therapeutic performance, safety profiles, and patient compliance. These medications are also easier to transport, store, and distribute across healthcare facilities, making them suitable for diverse medical environments. Unlike injectable treatments, oral therapies do not require specialized training for self-administration, which helps reduce the burden on healthcare professionals while simplifying treatment routines for patients. In addition, many individuals prefer oral medications because they are more convenient and less invasive.
North America Incretin-based Drugs Market accounted for 45.7% share in 2025. The region continues to demonstrate significant growth potential, primarily due to the increasing number of individuals diagnosed with type 2 diabetes mellitus. The expanding patient population is driving demand for advanced therapeutic solutions capable of delivering sustained blood glucose management while addressing related metabolic challenges. Healthcare providers across the region are increasingly prescribing incretin-based therapies as part of comprehensive diabetes management strategies. These treatments offer effective long-term glycemic control and provide additional benefits such as weight management, which are highly relevant for patients dealing with chronic metabolic conditions. As the healthcare system focuses on improving long-term disease outcomes, incretin-based drugs are gaining broader acceptance among clinicians throughout North America.
Key participants operating in the Global Incretin-based Drugs Market include AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck, Novo Nordisk, Pfizer, Sanofi, Takeda Pharmaceutical Company, and Teva Pharmaceuticals. Companies active in the Incretin-based Drugs Market are implementing several strategic initiatives to reinforce their competitive position and expand global reach. Major pharmaceutical firms are prioritizing research and development investments to advance innovative formulations and improve therapeutic performance. Strategic partnerships and collaborative agreements with research institutions and biotechnology firms are also becoming common, allowing companies to accelerate drug development and expand product pipelines. Market participants are strengthening their presence in emerging healthcare markets through distribution expansion and localized commercialization strategies. In addition, organizations are focusing on regulatory approvals and clinical trials to support new product introductions and broaden therapeutic indications.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Drug Type, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Route of Administration, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Indication, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Distribution Channel, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
The companies profiled in this Incretin-based Drugs market report include:- AstraZeneca
- Boehringer Ingelheim
- Eli Lilly and Company
- GlaxoSmithKline
- Merck
- Novo Nordisk
- Pfizer
- Sanofi
- Takeda Pharmaceutical Company
- Teva Pharmaceuticals
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 135 |
| Published | March 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 39.4 Billion |
| Forecasted Market Value ( USD | $ 72.6 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
